Inventor
CIBLAT STEPHANE
CA35 patents
⚠️ This page may combine multiple inventors who share the name “CIBLAT STEPHANE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SYROS PHARMACEUTICALS INC
15 patentsUS10738067B2Aug 11, 2020
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC5 citations83
US10106526B2Oct 23, 2018
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC5 citations83
US10059690B2Aug 28, 2018
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC9 citations83
US10308648B2Jun 4, 2019
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC6 citations82
US11040957B2Jun 22, 2021
Heteroaromatic compounds useful for the treatment of proliferative diseases
SYROS PHARMACEUTICALS INC7 citations72
US10519135B2Dec 31, 2019
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC3 citations72
US11124527B2Sep 21, 2021
Compounds for the modulation of Myc activity
SYROS PHARMACEUTICALS INC2 citations69
US11311542B2Apr 26, 2022
Inhibitors of cyclin dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC3 citations66
US12240869B2Mar 4, 2025
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC1 citations63
US10865206B2Dec 15, 2020
Inhibitors of cyclin-dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC1 citations61
US11753418B2Sep 12, 2023
Compounds for the modulation of Myc activity
SYROS PHARMACEUTICALS INC0 citations59
US11274103B2Mar 15, 2022
Compounds for the modulation of MYC activity
SYROS PHARMACEUTICALS INC0 citations47
US11918592B2Mar 5, 2024
Inhibitors of cyclin dependent kinase 7 (CDK7)
SYROS PHARMACEUTICALS INC0 citations46
US11040981B2Jun 22, 2021
Pyrrolotriazine compounds and methods of inhibiting TAM kinases
SYROS PHARMACEUTICALS INC0 citations46
US10787444B2Sep 29, 2020
Compounds for the modulation of myc activity
SYROS PHARMACEUTICALS INC0 citations38
BANTAM PHARMACEUTICAL LLC
4 patentsUS10537558B2Jan 21, 2020
Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
BANTAM PHARMACEUTICAL LLC3 citations69
US11602526B2Mar 14, 2023
Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
BANTAM PHARMACEUTICAL LLC1 citations59
US11325903B2May 10, 2022
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
BANTAM PHARMACEUTICAL LLC2 citations57
US12150934B2Nov 26, 2024
Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
BANTAM PHARMACEUTICAL LLC0 citations44
PYRAMID BIOSCIENCES INC
3 patentsUS11739096B2Aug 29, 2023
5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer
PYRAMID BIOSCIENCES INC1 citations67
US11230546B2Jan 25, 2022
5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer
PYRAMID BIOSCIENCES INC2 citations67
US12486276B2Dec 2, 2025
5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer
PYRAMID BIOSCIENCES INC0 citations57